MedTrace Logo

Extension Study of GI198745 to Treat Benign Prostatic Hyperplasia

NCT00969072 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2010-09-13

No results posted yet for this study

Summary

The primary objective is to assess the safety of GI198745 0.05mg, 0.5mg, 2.5mg once daily for 52 weeks.

Conditions

  • Benign Prostatic Hyperplasia
  • Prostatic Hyperplasia

Interventions

DRUG

GI198745 0.05mg

GI198745 (drug) - benign prostatic hyperplasia

DRUG

GI198745 0.5mg

GI198745 (drug) - benign prostatic hyperplasia

DRUG

GI198745 2.5mg

GI198745 (drug) - benign prostatic hyperplasia

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2005-02-28
Completion
2005-02-28

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00969072 on ClinicalTrials.gov